Lastly, we demonstrated that HCC patients with increased highly activated circulating CD8+ T cells in their peripheral blood during pembrolizumab treatment achieved significant clinical benefit to pembrolizumab, while refractory patients demonstrated enrichments of CD14+/CD16+ monocytes and NK cells. Here, CD8A is linked to hepatocellular carcinoma.